|Description||ChemoKine therapuetics development|
|Venture Round, 6/04 |
|Series C, 8/06 |
|Series D, 3/07 |
ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.